

Cardioprotective effect of eicosapentaenoic acid during ischemia and reperfusion

Efeito cardioprotetor do ácido eicosapentaenóico durante a isquemia e reperfusão

Eduarda Santa-Helena^{1,2} , Camila Wally^{1,2} , Joaquim de Paula Ribeiro^{1,2} , Ana Paula de Souza Votto^{1,2} , Carla Amorim Neves Gonçalves^{1,2} 

1. Pós Graduação em Ciências Fisiológicas, Instituto de Ciências Biológicas, Universidade Federal do Rio Grande (FURG), Rio Grande, RS, Brasil. 2. Instituto de Ciências Biológicas, Universidade Federal do Rio Grande (FURG), Rio Grande, RS, Brasil

Abstract

Objective: In this work, rats isolated hearts were infused EPA before the ischemia period and during reperfusion for available get well in parameter relatives to redox reactions. **Methods:** The effect of EPA was tested on isolated hearts induced to ischemia and reperfusion, treatment occurred at different times (ischemia or reperfusion). Antioxidant capacity against peroxy radicals, glutathione cysteine ligase activity, glutathione concentration, lactate dehydrogenase, and creatine kinase concentration was analyzed. **Results:** Hearts treated with eicosapentaenoic acid had the minor generation of species reactive oxygen and lipid damage after reperfusion. The GSH concentration was higher when the hearts were treated with eicosapentaenoic acid in the period of reperfusion. **Conclusion:** In conclusion, this study demonstrates that the dose of EPA (20 μ M) used before ischemia can act as a cardioprotective antioxidant molecule, prevented damage heart from ischemic and reperfusion injury.

Keywords: Heart; Infarction; Myocardium; Omega 3; Oxidative Stress; Ischemia and Reperfusion.

Resumo

Objetivo: Neste trabalho, corações isolados de ratos foram infundidos com EPA antes do período de isquemia e durante a reperfusão para obtenção de melhora em parâmetros relativos às reações redox. **Métodos:** O efeito do EPA foi testado em corações isolados induzidos a isquemia e reperfusão, o tratamento ocorreu em diferentes momentos (isquemia ou reperfusão). A capacidade antioxidante contra os radicais peróxido, atividade da glutatona cisteína ligase, concentração de glutatona, lactato desidrogenase e concentração de creatina quinase foi analisada. **Resultados:** Corações tratados com ácido eicosapentaenóico tiveram a menor geração de espécies reativas de oxigênio e danos lipídicos após a reperfusão. A concentração de GSH foi maior quando os corações foram tratados com ácido eicosapentaenóico no período de reperfusão. **Conclusão:** Em conclusão, este estudo demonstra que a dose de EPA (20 μ M) utilizada antes da isquemia pode atuar como uma molécula antioxidante cardioprotetora, prevenindo danos ao coração por isquemia e lesão de reperfusão.

Palavras-chave: Coração; Infarto; Miocárdio; Omega 3; Estresse Oxidativo; Isquemia e reperfusão.

INTRODUCTION

Myocardial ischemia and reperfusion (IR) is a major contributor to morbidity and mortality in the world^{1,2}. The injury induced by myocardial IR may range from a small insult resulting in limited tissue damage to a large one leading to cellular death³. The ischemia may be total when the blood flow is insufficient to maintain tissue or cell life, or partial, which maintains cell viability, but with the risk of progression to cell death, depending on the tissue and time⁴. During reperfusion, with the return of mitochondrial activity and the consequent reactivation of the electron transport chain occur a large production of reactive oxygen species (ROS) and reactive nitrogen species occurs⁵. These reactive species, in turn, promote an attack on cardiolipin, a phospholipid located in the internal mitochondrial membrane, altering the membrane fluidity, ionic permeability, structure, and function of the components of the mitochondrial electron transport chain, resulting in reduced efficiency of mitochondrial oxidative phosphorylation⁶. In addition, ROS and reactive nitrogen species also cause the activation of ryanodine receptors, located in the sarcoplasmic reticulum, which

culminates in a large release of Ca²⁺ and further contributes to the overload of this ion in the cytosol⁷.

Omega-3 fatty acids like eicosapentaenoic acid (20:5n3 - EPA) and docosahexaenoic acid (22:6n3 - DHA) are polyunsaturated carboxylic acids (PUFA n-3), wherein the double bond is the third carbon from the opposite end to carboxyl⁸. The PUFAs n-3 are not only used in the clinical prevention of death from heart disease but also has a protective role in cardiac physiology, cardiovascular health, and prevention of heart diseases⁹. Among cardioprotective roles, many studies indicate that regular intake of PUFA n-3 improves some risk factors such as blood pressure, platelet reactivity and thrombosis, triglycerides levels, vascular function, arrhythmias, heart rate variability, and inflammation^{10, 11, 12, 13}. The daily recommendation is about 1g n-3 PUFAs/day as fish or fish oils as secondary prevention who has a coronary vascular disease; 2 to 4g/day for the treatment of hypertriglyceridemia; and fish oil three times/week (0.5g / day) for healthy individuals¹⁴.

Correspondence: Carla Amorim Neves Gonçalves. Instituto de Ciências Biológicas, Universidade Federal do Rio Grande - FURG, Av. Itália Km 8, CEP 96201-900, Rio Grande, RS - Brazil. Zip Code: 96203-900. E-mail address: camorimgon@gmail.com

Conflict of interest: The authors declare that there is no conflict of interest.

Received: 2020 Mar 528 Revised 2021 Abr 29; Accepted 2021 May 3

2 Efeitos da abordagem osteopática na doença pulmonar obstrutiva crônica

Most studies that seek to evaluate the effects of PUFAs on ischemia and reperfusion used as a source of omega 3 fish oils or make use of a mixture of EPA and DHA^{15,16}. Few articles seek to establish individual relationships of these substances with cardiac damage caused during ischemia and reperfusion. Considering this background, the objective of this study was to evaluate the imbalance of redox owing to acute treatment with eicosapentaenoic acid in different moments of ischemia and reperfusion in an ex vivo model of rat heart.

METHODS AND MATERIALS

Animals

This research protocol was approved by the Animal Care and Ethical Use Committee of the Federal University of Rio Grande (P019/2013), RS, Brazil. Thirty-five male rats (Wistar, weighting 300-400g) were obtained from the Central Animal House of the Federal University of Rio Grande do Sul, RS, Brazil. They were maintained on a 12h light/12h dark cycle in constant temperature 21±1°C and received commercial rodent food (25g/animal/day) and water “*ad libitum*”.

Preparation of Eicosapentaenoic Acid (EPA) solution stock

To prepare the stock solution cis-^{5,8,11,14,17}-Eicosapentaenoic acid (Sigma-Aldrich), 100mg/ml ethanol P.A., remaining at -15°C. Aliquots were used and diluted in Krebs-Heinselet buffer to have a final work solution of 20µM of EPA to treat isolated hearts before the ischemia and during reperfusion.

Ex vivo model of ischemia and reperfusion in isolated heart

Ischemia/Reperfusion was conducted in a Langendorff system¹⁷. Rats were ended by decapitation and the hearts were removed and immediately the ascending aorta was cannulated. The heart was subjected to retrograde perfusion with Krebs-Henseleit buffer (118mM NaCl, 4.7mM KCl, 1.2mM KH₂PO₄, 1.2mM MgSO₄.7H₂O, 25mM NaHCO₃, 2.5mM CaCl₂, and 11.1mM Glucose) equilibrated with 95% oxygen and 5% carbon dioxide to a pH of 7.4. Non-recycling perfusion was initiated at a constant flow rate of 10ml/min with 90mmHg of basal pressure, at 37°C. The perfusion buffer was previously filtered through a 0.22µm membrane to remove any aggregated particles. Hearts were perfused with Krebs buffer for 10 min (stabilization period), then underwent a period of global ischemia (15 min), followed by 15 min of reperfusion.

The isolated heart submitted to Langendorff preparation and after 10 minutes of stabilization was divided into the following groups (n = 7 / group): C - control (perfusion for 45 minutes), IR - ischemia and reperfusion (15 minutes of stabilization, 15 minutes of ischemia and sequentially 15 minutes of reperfusion), Epa - eicosapentaenoic acid (15 minutes of stabilization after infusion with EPA for another 15 minutes followed by 15 minutes of infusion), treatment with Eicosapentaenoic acid

EpaIR immediately before ischemia and reperfusion (perfusion) with EPA for 15 minutes followed by 15 minutes of ischemia and 15 minutes of reperfusion) and IEpa-R (15 minutes of stabilization followed by 15 minutes of ischemia and 15 minutes of reperfusion with EPA) (for details, see Table 1).

Table 1. Experimental design. Eicosapentaenoic acid (EPA) treatment in ex vivo heart during ischemia and reperfusion.

Groups	Stabilization period 15 min	Ischemia period 15 min	Reperfusion period 15 min
Control	Buffer infusion	Buffer infusion	Buffer infusion
I/R	Buffer infusion	Ischemia	Buffer infusion
Epa	Buffer infusion	Epa infusion	Buffer infusion
EpaIR	Epa infusion	Ischemia	Buffer infusion
IEpaR	Buffer infusion	Ischemia	Epa infusion

Measurement of lactate dehydrogenase (LDH) and creatine kinase (CK) enzymes activities

For the determination of the activity of these enzymes, the perfusate was collected during the reperfusion period, then the kit was used to determine LDH activity (LabTeste) and Creatine kinase (CK) levels (from the CK-MB Liquiform-Labtest kit) at 340 nm in a spectrophotometer according to the manufacturer's instructions.

The amount of CK produced was expressed as U / L tissue and the factor of 8121 was used for the calculation.

Measurement of total antioxidant capacity (ACAP)

Total antioxidant competence against peroxy radicals was analyzed through ROS determination in hearts treated or not with a peroxy radical generator. Peroxy radicals were produced by thermal (35°C) decomposition of 2, 2'-azobis 2 methylpropionamide dihydrochloride (ABAP; 4mM; Aldrich) e. Readings were carried through in a fluorescence microplate reader (Victor 2 Perkin), in a medium containing 30 mM HEPES (pH 7.2), 200 mM KCl, 1 mM MgCl₂, 40 µM DCF-DA. The results were expressed as area difference of FU x min in the same sample with and without ABAP addition and standardized to the ROS area without ABAP (background area)¹⁸.

Glutamate cysteine ligase activity and glutathione concentration

Glutamate cysteine ligase (GCL) activity and baseline glutathione (GSH) level were determined based on the reaction of naphthalenedicarboxialdehyde (NDA) with GSH or γ-glutamylcysteine (γ-GC) to form cyclized products that are highly fluorescent. Briefly, samples for GCL activities and GSH levels were kept on ice until transferred, at 15 s time intervals, to the corresponding 96-well reaction late (25°C) containing

25µL of the reaction solution. After a pre-incubation of 5 min, the GCL reaction was initiated by adding 25µL of cysteine (2mM). The plate was incubated for 60 min and the reaction stopped by adding 25µL of 5-sulfosalicylic acid (SSA, 200mM). The plate was then centrifuged for 5 min at 2.000 G and 20µL aliquots of supernatant were transferred to a new 96-well plate. GSH reaction was initiated by adding 180µL of naphthalene carboxaldehyde (NDA). NDA-GSH and NDA-GCL fluorescence intensities were measured on a fluorescence microplate reader at 450 nm excitation/535 nm emission, respectively (FilterMax F5, Molecular Devices).

Statistical Analysis

Data were expressed as mean \pm S.E. ANOVA assumptions of normality and homoscedasticity were tested by Kolmogorov-Smirnov and Levene's tests, respectively, and when they were not reached, data were mathematical transformed (square root) and performed by one-way ANOVA or were tested by non-parametric analysis of variance of Kruskal-Wallis. Significant differences were tested by a posteriori Tukey HSD test. Statistical significance was accepted if $p < 0.05$.

RESULTS

Lactate dehydrogenase (LDH) activity and creatine kinase levels (CK)

The EpaIR group had a minor activity LDH and CK when compared to the IR group ($p < 0.05$) (Figure 1). The treatment with EPA during reperfusion did not show significant alterations in activity LDH and CK in relation to IR ($p > 0.05$). (Figure 1).

Total antioxidant capacity

In respect of total antioxidant capacity against peroxy radicals (ACAP), it was observed that isolated hearts did show significant differences between Control and Epa groups ($p > 0.05$, Figure 2). However, the IR group demonstrates a depletion in antioxidant capacity when compared to the control ($p < 0.05$). When Epa treatment was administered in the pre-ischemic period it was also observed a decrease in ACAP ($p < 0.05$). When Epa was administered during reperfusion no change in the myocardium antioxidant capacity was observed (Figure 2).

Glutamate cysteine ligase activity and glutathione concentration

The GCL activity does not show a significant difference between groups control, IR, Epa, and Epa PI. However, an increase was observed in EPA R when compared to control and IR ($p < 0.05$). The GSH concentration was not different among control, IR, Epa, and EpaPI groups (Figure 3B), but when compared with other groups, the EpaR presented a higher GSH concentration (Figure 3B) ($p < 0.05$).

Figure 1. The activity LDH (A) and CK (B) in perfusate after reperfusion treated with Eicosapentaenoic acid (Epa). Figure A. LDH activity in control hearts (Control), comparing to ischemia/reperfusion (IR) and Epa treated with Epa before ischemia (EpaIR) and during reperfusion (IEpaR) related to IR. Figure B. CK activity in control hearts (control), comparing to ischemia/reperfusion (IR) and Epa treated with Epa before ischemia (EpaIR) and during reperfusion (IEpaR) related to IR. Different letters mean statistically significant differences ($p < 0.05$).




Figure 2. Antioxidant capacity against peroxy radical (ACAP) from isolated hearts during ischemia and reperfusion treated with Eicosapentaenoic acid (Epa). ACAP in control hearts (Control), comparing to ischemia/reperfusion (IR) and Epa, antioxidant capacity with Epa treatment before ischemia (EpaIR) and during reperfusion (IEpaR) in relation to IR. Different letters mean statistically significant differences ($p < 0.05$).





Figure 3. Glutamate cysteine ligase activity and glutathione concentration in isolated hearts during ischemia and reperfusion treated with Eicosapentaic acid (Epa). Figure A. GCL activity in control hearts (Control), comparing to ischemia/reperfusion (IR) and Epa, GCL activity in hearts treated with Epa before ischemia (EpaIR) and during reperfusion (IEpaR) related to IR. Figure B. GSH concentration in control hearts (control), comparing to ischemia/reperfusion (IR) and Epa, GSH concentration in hearts treated with Epa before ischemia (EpaIR) and during reperfusion (IEpaR) related to IR. Different letters mean statistically significant differences ($p < 0,05$).



DISCUSSION

Diets rich in n-3 polyunsaturated fatty acids are considered effective in preventing many diseases^{19,20}. However, its susceptibility to oxidation of free radicals was directly correlated to the degree of unsaturation of the molecule, but it is not common to know whether or which PUFA has pro or anti-oxidant effects²⁰. Fatty acids linoleic acid (LA), alpha-linolenic acid (ALA), arachidonic acid (ARA), EPA, and DHA (60 μM) compared to each other, in a study with HepG2 (human hepatoma cells) demonstrate a reduction in cell viability (except for DHA). Increased activity of antioxidant enzymes (SOD, glutathione s-transferase, and glutathione peroxidase) by DHA, LA, and ALA, and high levels of glutathione (by DHA and ALA) have also been observed, indicating a related pro-oxidant or differential antioxidant capacity to fatty acid type²⁰. None of the tested fatty acids modified the cell's total antioxidant activity.

High levels of oxidative stress have been observed in rats with intracerebral hemorrhagic stroke, along with decreased

superoxide dismutase activity and glutathione concentration and increased lipid peroxidation, when supplemented with 1% EPA and DHA of total energy consumption²¹. In addition, increased consumption of fish oil produced increased lipid peroxidation in adult males with diet-rich salmon²² and increased oxidative DNA damage in rat hepatocytes²³. In contrast, our results suggest that treatment with EPA during reperfusion managed to have a protective effect since it kept the ACAP values equal to the control group. Treatment with EPA (20 μM) during reperfusion also caused an increase in glutathione content. Both results confirm a positive EPA cardioprotective action.

When myocardial cells, containing LDH and CK-MB are damaged due to deficient oxygen supply or glucose, the cell membrane becomes permeable or may rupture, which results in the leakage of enzymes. Richard et al.¹⁵ reported a reduction in lipid peroxidation and infarct size and CK activity when the isolated heart was pre-treated and pre and pos-treated with DHA. In the present study, the administration of EPA (20 μM) before IR (EpaIR Group) significantly decreased LDH and CK levels.

Literature has a lot of examples of similar antioxidant effects from polyunsaturated fatty acids in different target tissues, generally administered as a mixture of PUFAs n-3, and from natural or synthetic sources. Working with chronic treatment using DHA and EPA mixture during renal ischemia and reperfusion in rats, a decrease in the lipid peroxidation and increase in the activity of catalase (CAT) and superoxide dismutase (SOD) was verified²⁴. There are pieces of evidence that dietary fish oil may decrease brain stroke volume by means of increase the activity of antioxidant enzymes and reduce lipoperoxidation²⁵. Few articles present effects of isolated fatty acids in myocardium infarction²⁶ or endothelial cells^[33, 34]. Infusion of DHA isolated protects against myocardial infarction in a study with a similar methodology²⁶. This research also utilizing isolated rat heart preparation, tested DHA (2.5 μM) 10 min before a protocol of 20 min of global ischemia and 30min of reperfusion or infusion DHA 10 min pre-ischemia plus another infusion of 10 min after ischemia. These authors observed that DHA lowered oxygen and ATP myocardium consumption, reduced infarct size, release creatine kinase, and diminished lipid peroxidation²⁶. Fish oil consumption has been indicated because of its proprieties to stimulate neovascuogenesis, mainly through the effects of EPA, exerting prevention to ischemic injury, as saw in vitro human endothelial progenitor cells²⁷. Chronic treatment of human coronary endothelial cells with low physiological concentrations of DHA enhanced endothelial nitric oxide synthase and Akt activity, and increase de NO bioavailability, improving endothelial function²⁸. This work predicts that only Epa, especially when administered before ischemia or during reperfusion, acts as an antioxidant molecule, reducing oxidative damage in the isolated heart of rats.

CONCLUSION

The present ex vivo IR protocol did not activate the ACAP system, or the GCL-GSH cycle, in addition to increasing CK and

5 Efeitos da abordagem osteopática na doença pulmonar obstrutiva crônica

LDH levels, a classic change in infarction.

Acute treatment with EPA alone (20 μ M) was first tested in isolated IR hearts, and the results indicate that pre-ischemia and during reperfusion treatment can reduce cardiac damage. These findings indicate that the accuracy of acute therapy depends on the time of administration. Our hypothesis is that higher doses/treatment time during reperfusion should be necessary to protect the heart from damage to IR. In conclusion, the time, dose, and the most effective time for

cardioprotection in the isolated heart of rats were determined as 20 μ M eicosapentaenoic acid, delivered fifty minutes before the ischemia and reperfusion induction.

FINANCING NOTE REQUIRED BY CAPES

This work was carried out with the support of the Higher Education Personnel Improvement Coordination - Brazil (CAPES) - Financing Code 001.

REFERENCES

1. World Health Organization. World health statistics. Geneva: WHO; 2012. 178p
2. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart diseases and stroke statistics 2010-update: a report from the American Heart Association. *Circulation*. 2010 Feb; 121(7): e46-e215. doi: 10.1161/CIRCULATIONAHA.109.192667.
3. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. *J Clin Invest*. 2013 Jan; 123(1): 92-100. doi: 10.1172/JCI62874.
4. Powers SK, Quindry JC, Kavazis AN. Exercise-Induced cardioprotection against myocardial ischemia-reperfusion injury. *Free Radic Biol Med*. 2008 Jan; 44(2): 193-201. doi: 10.1016/j.freeradbiomed.2007.02.006.
5. Walters AM., Porter GA, Brookes PS. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. *Circ Res*. 2012; 111(9): 1222-1236. doi: 10.1161/CIRCRESAHA.112.265660.
6. Paradies G, Petrosillo G, Paradies V, & Ruggiero FM. Role of cardiolipin peroxidation and Ca²⁺ in mitochondrial dysfunction and disease. *Cell calcium*, 2009 Jun; 45(6): 643-650. doi: 10.1016/j.ceca.2009.03.012.
7. Köhler AC, Sag CM, Maier LS. Reactive oxygen species and excitation-contraction coupling in the context of cardiac pathology. *J Mol Cell Cardiol*. 2014 Aug; 73: 92-102. doi: 10.1016/j.yjmcc.2014.03.001.
8. Evora PRB, Pearson PJ, Seccombe JF, Schaff HV. Lesão de Isquemia-reperfusão. Aspectos Fisiopatológicos e a Importância da Função Endotelial. *Arq Bras Cardiol*. 1996; 66(4): 239-245.
9. Ruxton CHS, Derbyshire E. Latest evidence on omega-3 fatty acids and health. *Nutr Food Science*. 2009 Jul; 39(4): 423-438. doi: 10.1108/00346650910976293.
10. Hibbeln JR, Nieminen LRG, Blasbalg TL, Riggs JA, Lands WEM. Healthy intakes of n-3 and n-6 fatty acids. Estimations considering worldwide diversity. *Am J Clin Nutr*. 2006 Jun; 83(6 Suppl):1483-1493. doi: 10.1093/ajcn/83.6.1483S.
11. Zhao YT, Chen Q, Sun YX, Li XB, Zhang P, Xu Y, Guo JH. Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials. *Ann Med*. 2009; 41(4): 301-310. doi: 10.1080/07853890802698834.
12. Mozaffarian D, Wu JHY. Omega-3 fatty acids and cardiovascular disease effects on risk factors, molecular pathways, and clinical events. *J Am Coll Cardiol*. 2011 Nov; 58(20): 2047-2067. doi: 10.1016/j.jacc.2011.06.063.
13. Musa-Veloso K, Binns MA, Kocenas A, Chung C, Rice H, Oppedal-Olsen H, Lloyd H, Lemke S. Impact of low v. moderate intakes of long-chain n-3 fatty acids on risk of coronary heart disease. *Brit J Nutr*. 2011 Oct; 106(8): 1129-1141. doi: 10.1017/S0007114511001644.
14. Geleijnse JM, Giltay EJ, Grobbee DE, Donders ART, Kok FJ. Blood pressure response to fish oil supplementation: meta-regression analysis of randomized trials. *J Hypertens*. 2002 Aug; 20(8): 1493-9. doi: 10.1097/00004872-200208000-00010.
15. British Nutrition Foundation. Unsaturated fatty acids: nutritional and physiological significance. London: Chapman & Hall; 1992.
16. Von Schacky C. Omega-3 fatty acids: antiarrhythmic, proarrhythmic or both? *Curr Opin Clin Nutr Metab Care*. 2008 Mar; 11(2): 94-9. doi: 10.1097/MCO.0b013e3282f44bdf.
17. Richard D, Oszust F, Guillaume C, Millart H, Laurent-Maquin D, Brou C, Bausero P, Visioli F. Infusion of docosahexaenoic acid protects against myocardial infarction. *Prostaglandins Leukot Essent Fatty Acids*. 2014 Apr; 90(4): 139-43. doi: 10.1016/j.plefa.2014.01.001.
18. Tsubaraya R, Yasuda S, Ito Y, Shiroto T, Gao JY, Ito K, et al. Eicosapentaenoic acid reduces ischemic ventricular fibrillation via altering monophasic action potential in pigs. *J Mol Cell Cardiol*. 2011 Sep; 51(3): 329-336. doi: 10.1016/j.yjmcc.2011.05.018.
19. Amado LL, Garcia ML, Ramos PB, Freitas RF, Zafalon B, Ferreira JLR, Yunes JS, Monserrat JM. A method to measure total antioxidant capacity against peroxyl radicals in aquatic organisms: Application to evaluate microcystins toxicity. *Sci Total Environ*. 2009 Mar; 407(6): 2115-2123. doi: 10.1016/j.scitotenv.2008.11.038.
20. Oakes KD, Van Der Kraak GJ. Utility of the TBARS assay in detecting oxidative stress in white sucker (*Catostomus commersoni*) populations exposed to pulp mill effluent. *Aquat Toxicol*. 2003 May; 63(4): 447-463. doi: 10.1016/s0166-445x(02)00204-7.
21. White CC, Viernes H, Krejsa CM, Botta D, Kavanagh TJ. Fluorescence-based microtiter plate assay for glutamate-cysteine ligase activity. *Anal Biochem*. 2003 Jul; 318(2): 175-180. doi: 10.1016/s0003-2697(03)00143-x.
22. Zgheer F, Alhosin M, Rashid S, Burban M, Auger C, & Schini-Kerth VB. Redox-sensitive induction of Src/PI3-kinase/Akt and MAPKs pathways activate eNOS in response to EPA: DHA 6: 1. *PloS one*. 2014 Aug; 9(8): e105102. doi: 10.1371/journal.pone.0105102.
23. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. *Exp. Biol. Med*. 2008 Jun; 233(6): 674-688. doi: 10.3181/0711-MR-311.
24. Di Nunzio M, Valli V, Bordoni A. Pro- and anti-oxidant effects of polyunsaturated fatty acid supplementation in HepG2 cells. *Prostaglandins Leukot Essent Fatty Acids*. 2011 Sep-Oct; 85(3-4): 121-127. doi: 10.1016/j.plefa.2011.07.005.
25. Park Y, Nama S, Yib H-J, Hong H-J, Leed M. Dietary n-3 polyunsaturated fatty acids increase oxidative stress in rats with intracerebral hemorrhagic stroke. *Nutr Res*. 2009 Nov; 29(11): 812-818. doi: 10.1016/j.nutres.2009.10.019.
26. Nelson GJ, Morris VC, Schmidt PC, Levander O. The urinary excretion of thiobarbituric acid reactive substances and malondialdehyde by normal adult males after consuming a diet containing salmon. *Lipids*. 1993 Aug; 28(8): 757-61. doi: 10.1007/BF02536000.
27. Kikugawa K, Yasuhara Y, Ando K, Koyama K, Hiramoto K, Suzuki M. Effect of supplementation of n-3 polyunsaturated fatty acids on oxidative stress-induced DNA damage of rat hepatocytes. *Biol Pharm Bull*. 2003 Sep; 26(9): 1239-44. doi: 10.1248/bpb.26.1239.

6 Efeitos da abordagem osteopática na doença pulmonar obstrutiva crônica

28 Choi-Know S, Park K-A, Lee H-J, Park M-S, Lee J-H, Jeon S-E, et al. Temporal changes in cerebral antioxidant enzyme activities after ischemia and reperfusion

in a rat focal brain ischemia model: effect of dietary fish oil. *Brain Res Dev Brain Res.* 2004 Aug; 152(1): 11-18. doi: 10.1016/j.devbrainres.2004.05.004.

Como citar este artigo/How to cite this article:

Santa-Helena E, Wally C, Ribeiro JP, Votto APS, Gonçalves CAN. Efeito cardioprotetor do ácido eicosapentaenóico durante a isquemia e reperfusão. *J Health Biol Sci.* 2021; 9(1):1-6.

J. Health Biol Sci. 2021; 9(1):1-6